This paper is only available as a PDF. To read, Please Download here.
Abstract
The effect of food intake on the pharmacokinetics of sustained-release (SR) morphine
sulfate capsules was assessed in 24 healthy male volunteers. Subjects were randomized
to receive a single, 20-mg SR morphine sulfate capsule while fasting and immediately
after consumption of a standard high-fat meal. Plasma samples were masked for pharmacokinetic
analysis. Although the extent of absorption of the SR preparation was comparable in
subjects in the fed and fasted states, plasma morphine concentrations were significantly
lower at most sampling times up to 10 hours when the drug was administered after a
high-fat meal. The rate of absorption of morphine from the SR capsule was slower with
food intake as evidenced by a 13% decrease in the maximum concentration (Cmax), a 28% increase in the half-life of absorption, and a 19% increase in the time to
Cmax. Results of this study indicate that food intake had an effect on the overall plasma-concentration-versus-time
profile of the SR morphine sulfate oral preparation, the extent of which was not revealed
by a comparison of Cmax and area under the plasma concentration—time curve values alone.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer pain relief and palliative care.Technical Report Series 804. World Health Organization, Geneva1990
- Management of cancer pain. Clinical Practice Guideline No. 9.AHCPR Publication No. 94-0592. US Department of Health and Human Services, Agency for Health Care Policy and Research, Rockville, Md1994
- Controlled-release morphine bioavailability (MS Contin® Tablets) in the presence and absence of food.Hospice J. 1990; 6: 17-30
- A single-dose study of the effect of food ingestion and timing of dose administration on the pharmacokinetic profile of Roxanol SR 30 mg (sustained-release morhine sulfate) tablets.Curr Ther Res. 1990; 47: 869-878
- Influence of a high-fat meal on the absorption of morphine from oral solution.Clin Pharmacol Ther. 1989; 46: 463-468
- Guidelines for oral extended (controlled) release dosage forms in vivo bioequivalence and in vitro dissolution testing. Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Md1993
- Single dose pharmacokinetics of Kapanol™, a new oral sustained-release morphine formulation.Drug Invest. 1994; 7: 262-274
- Once a day (i.e. 24 hourly) Kapanol™, a new sustained release morphine formulation, in the treatment of cancer pain: Pharmacokinetic aspects.Eur J Cancer. 1995; 31 (Abstract 897): S187
- A comparison of Kapanol (a new sustained-release morphine formulation), MST Continus, and morphine solution in cancer patients: Pharmacokinetic aspects of morphine and morphine metabolites.in: Gebhart GF Hammond DL Jensen TS Proceedings of the 7th World Congress on Pain. Progress in Pain Management. 2. IASP Press, Seattle, Wash1994
Article info
Identification
Copyright
© 1997 Published by Elsevier Inc.
